SRDX - Surmodics, Inc.
| Previous Close | 44.49 |
| Open | 43.90 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 42.61 - 44.67 |
| 52 Week Range | 38.06 - 82.35 |
| Volume | 58,676 |
| Avg. Volume | 111,093 |
| Market Cap | 575.689M |
| Beta (3Y Monthly) | 1.65 |
| PE Ratio (TTM) | 255.57 |
| EPS (TTM) | 0.17 |
| Earnings Date | Nov 14, 2017 - Nov 20, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 70.75 |
- Simply Wall St.
An Intrinsic Calculation For Surmodics, Inc. (NASDAQ:SRDX) Suggests It's 40% Undervalued
How far off is Surmodics, Inc. (NASDAQ:SRDX) from its intrinsic value? Using the most recent financial data, we'll...
- Zacks
Haemonetics (HAE) Beats on Q1 Earnings, Raises '19 EPS View
Haemonetics (HAE) Q1 performance by all business sections has been impressive, except for BloodCenter.
- Zacks
BioScrip Closes Option Care Merger, Incurs Wider Q2 Loss
With the conclusion of BioScrip (BIOS)-Option Care consolidation, the newly formed company gets its new name Option Care Health, Inc. under the ticker symbol BIOS.
- Zacks
Orthofix Medical (OFIX) Beats on Q2 Earnings, Margins Down
Orthofix Medical's (OFIX) Q2 performance across all business segments has been commendable, except for spinal implants.
- Zacks
Surging Earnings Estimates Signal Upside for SurModics (SRDX) Stock
SurModics (SRDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- Thomson Reuters StreetEvents
Edited Transcript of SRDX earnings conference call or presentation 31-Jul-19 9:00pm GMT
Q3 2019 Surmodics Inc Earnings Call
- Zacks
Surmodics (SRDX) Q3 Earnings Beat Estimates, Guidance Raised
Surmodics (SRDX) continues to gain from core Medical Devices unit, which saw significant contribution from the SurVeil deal with Abbott in Q3.
Motley FoolSurModics (SRDX) Q3 2019 Earnings Call Transcript
SRDX earnings call for the period ending June 30, 2019.
- Business Wire
Surmodics Reports Third Quarter Fiscal 2019 Results and Raises Fiscal 2019 Revenue and EPS Guidance
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2019 third quarter ended June 30, 2019, and updated its financial outlook for fiscal 2019.
- Simply Wall St.
Before You Buy Surmodics, Inc. (NASDAQ:SRDX), Consider Its Volatility
If you're interested in Surmodics, Inc. (NASDAQ:SRDX), then you might want to consider its beta (a measure of share...
- Business Wire
Surmodics to Webcast Third Quarter Fiscal 2019 Earnings Conference Call on July 31
Surmodics, Inc. (SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its third quarter fiscal 2019 conference call on Wednesday, July 31, at 4 p.m. CT (5 p.m. ET). The Company will issue an earnings news release after the market closes that afternoon. Gary Maharaj, president and chief executive officer, and Tim Arens, vice president of finance and chief financial officer, will recap the third quarter fiscal 2019 financial results and accomplishments.
- Zacks
PRGO or SRDX: Which Is the Better Value Stock Right Now?
PRGO vs. SRDX: Which Stock Is the Better Value Option?
- Zacks
Here's Why You Should Hold on to Surmodics (SRDX) Stock Now
Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.
- Zacks
Are Options Traders Betting on a Big Move in Surmodics (SRDX) Stock?
Investors need to pay close attention to Surmodics (SRDX) stock based on the movements in the options market lately.
- Insider Monkey
Hedge Funds Have Never Been More Bullish On SurModics, Inc. (SRDX)
Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]
- Simply Wall St.
When Should You Buy Surmodics, Inc. (NASDAQ:SRDX)?
Surmodics, Inc. (NASDAQ:SRDX), which is in the medical equipment business, and is based in United States, received a...
- Zacks
Zacks.com featured highlights include: LexinFintech, Veeco, Helen of Troy, Surmodics and Herman Miller
Zacks.com featured highlights include: LexinFintech, Veeco, Helen of Troy, Surmodics and Herman Miller
- Zacks
Why Is SurModics (SRDX) Down 6.2% Since Last Earnings Report?
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
New Analyst Coverage Puts Spotlight on These 5 Stocks
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
- Business Wire
Surmodics to Present at Jefferies Healthcare Conference
Surmodics, Inc. (SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Tim Arens, vice president of finance and chief financial officer, will make a presentation to the investment community at the Jefferies 2019 Healthcare Conference in New York City on Tuesday, June 4, 2019, at 10:30 a.m. ET (9:30 a.m. CT). A live audio webcast of the presentation will be available by going to the investor relations portion of the Company’s website at https://surmodics.gcs-web.com and clicking on the webcast icon.
- Zacks
Zacks.com featured highlights include: LexinFintech, Herman Miller, Interactive Brokers, ConnectOne and Surmodics
Zacks.com featured highlights include: LexinFintech, Herman Miller, Interactive Brokers, ConnectOne and Surmodics
- Zacks
5 Stocks to Keep an Eye on as Analysts Initiate Coverage
More analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
- Simply Wall St.
Did Surmodics, Inc. (NASDAQ:SRDX) Insiders Sell Shares?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
- Insider Monkey
Hedge Funds Have Never Been This Bullish On SurModics, Inc. (SRDX)
Hedge funds run by legendary names like George Soros and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]
- Zacks
Surmodics (SRDX) Q2 Earnings and Revenues Beat Estimates
Surmodics (SRDX) consistently gains traction from its core Medical Devices unit, which witnesses a substantial contribution from the SurVeil pact with Abbott.
